DeepMed Research

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori SRL

🇷🇴Romania

Country: 🇷🇴Romania

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Yoga on QOL Physiological Distress&Fatigue, on Patients Affected by Breast Cancer in Adjuvant Radiotherapy

Not Applicable

Conditions: Fatigue
Female Breast Cancer
Quality of Life
Physiological Stress
Radiotherapy; Complications

Interventions: Behavioral: Yoga lessons

First Posted Date: 2021-03-01

Last Posted Date: 2021-03-01

Lead Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Target Recruit Count: 120

Registration Number: NCT04775290

Locations: 🇮🇹
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST s.r.l., Meldola, Forlì-Cesena, Italy

Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination With 5-Fluorouracil (5FU) /or in FOLFIRI Regimen

Completed

Conditions: Gastrointestinal Cancer
CALCIUM LEVOFOLINATO (Ca-lev)
SODIUM LEVOFOLINATO (Na-lev)

First Posted Date: 2020-12-22

Last Posted Date: 2020-12-22

Lead Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Target Recruit Count: 64

Registration Number: NCT04680104

Key Performance Indicators for the Assessment of NSCLC Patients Pathway

Completed

Conditions: Non Small Cell Lung Cancer

First Posted Date: 2020-12-21

Last Posted Date: 2020-12-21

Lead Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Target Recruit Count: 430

Registration Number: NCT04676321

Locations: 🇮🇹
IRCCS Arcispedale S.Maria Nuova, Reggio Emilia, RE, Italy
🇮🇹
Policlinico of Modena, Modena, Italy
🇮🇹
IRST, Meldola, Forlì-Cesena, Italy

What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer?

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Diagnostic Test: screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice

First Posted Date: 2020-10-19

Last Posted Date: 2024-12-09

Lead Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Target Recruit Count: 60000

Registration Number: NCT04590560

Locations: 🇮🇹
Irst Irccs, Meldola (FC), FC, Italy
🇮🇹
Istituto per lo studio, la prevenzione e la rete oncologica (ISPRO), Firenze, Italy
🇮🇹
AUSL Romagna, Forlì, Italy

and more 1 locations

Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma

Phase 2

Recruiting

Conditions: Glioblastoma
Vaccination

Interventions: Biological: Autologous Dendritic Cells (DC) vaccine
Drug: Temozolomide

First Posted Date: 2020-08-24

Last Posted Date: 2023-02-17

Lead Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Target Recruit Count: 28

Registration Number: NCT04523688

Locations: 🇮🇹
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, FC, Italy

Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)

Phase 2

Terminated

Conditions: Hydroxychloroquine
Prophylaxis
Treatment
SARS-CoV-2
COVID19

Interventions: Drug: Hydroxychloroquine

First Posted Date: 2020-04-27

Last Posted Date: 2025-03-10

Lead Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Target Recruit Count: 155

Registration Number: NCT04363827

Locations: 🇮🇹
Irst Irccs, Meldola, FC, Italy

Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.

Conditions: SARS-CoV-2
COVID-19

Interventions: Genetic: Next generation Sequencing (NGS) analysis
Other: serological test
Other: Rapid molecular test
Other: serum chemistry analysis

First Posted Date: 2020-04-14

Last Posted Date: 2020-04-15

Lead Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Target Recruit Count: 500

Registration Number: NCT04345315

Locations: 🇮🇹
Irst Irccs, Meldola, FC, Italy
🇮🇹
UO Microbiologia,Centro Servizi Pievesestina, AUSL Romagna, Cesena, FC, Italy

Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Other: molecular characterization

First Posted Date: 2020-03-09

Last Posted Date: 2025-04-10

Lead Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Target Recruit Count: 300

Registration Number: NCT04300101

Locations: 🇮🇹
Ospedale S. Maria delle Croci RAVENNA, Ravenna, RA, Italy
🇮🇹
Irst Irccs, Meldola, FC, Italy
🇮🇹
L'Azienda Ospedaliero-Universitaria Di Bologna Policlinico S. Orsola-Malpighi, Bologna, Italy

and more 1 locations

Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies

Recruiting

Conditions: Haematologic Disease
Haematological Malignancy

Interventions: Other: clinical data and sample collection

First Posted Date: 2020-03-06

Last Posted Date: 2024-07-01

Lead Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Target Recruit Count: 2000

Registration Number: NCT04298892

Locations: 🇮🇹
Ospedale Ca' Foncello Treviso, Treviso, Italy
🇮🇹
IRCSS Istituto Tumori, Bari, Italy
🇮🇹
IRCCS Fondazione Policlinico Universitario A. Gemelli, Roma, Italy

and more 23 locations

A Phase II Study on Adjuvant Vaccination With Dendritic Cells Loaded With Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.

Phase 2

Recruiting

Conditions: Neuroendocrine Tumors
Vaccination
Head Neck Tumors
Soft Tissue Sarcoma
Rare Cancer

Interventions: Biological: Autologous DC vaccine
Drug: Interleukin-2

First Posted Date: 2019-11-18

Last Posted Date: 2020-04-22

Lead Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Target Recruit Count: 51

Registration Number: NCT04166006

Locations: 🇮🇹
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, FC, Italy

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy